Market Cap 158.99M
Revenue (ttm) 57.80M
Net Income (ttm) -97.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -169.45%
Debt to Equity Ratio 0.00
Volume 8,105,600
Avg Vol 6,144,390
Day's Range N/A - N/A
Shares Out 336.50M
Stochastic %K 59%
Beta 1.28
Analysts Sell
Price Target $3.25

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 970 6000
Address:
501 Canal Blvd, Richmond, United States
NorthStarStats
NorthStarStats Feb. 26 at 2:05 AM
I forgot to post yesterday's stocks. Hopefully they did well today: $PRME Score: 100, $GMED Score 100, $EDIT Score 100, $LRMR Score 100, $SGMO Score 100
0 · Reply
Swamp_Yankee
Swamp_Yankee Feb. 26 at 12:06 AM
$SGMO Did you all catch JimiJo and metho on with Jim Crammer tonight? They clearly laid out the whole up and down. Great stuff.
1 · Reply
kiwiSurfer
kiwiSurfer Feb. 25 at 11:53 PM
$SGMO bingo
0 · Reply
Swamp_Yankee
Swamp_Yankee Feb. 25 at 11:51 PM
$SGMO Sandy won’t come out of his bedroom. He is all bent out of shape that Hellebuyck is getting the Presidential Medal of Freedom and not him. He is on his 3rd Papa John’s small cheese pizza.
0 · Reply
TheFrenchBuzz
TheFrenchBuzz Feb. 25 at 9:42 PM
$SGMO 2. Broker Votes: Can they vote on your behalf? This is the most strategic part for Sangamo’s management: "Routine" vs. "Non-Routine" Votes: Under stock exchange rules (NYSE/Nasdaq Rule 452), brokers are not allowed to vote without instructions on "important" matters (like electing directors or mergers). Reverse Splits are "Routine": Generally, a reverse split is classified as a routine matter by the exchanges because it doesn't change the intrinsic value of the investment. The Consequence: If you do not send voting instructions to your broker by the deadline, the broker has discretionary power to vote for you. In the vast majority of cases, brokers vote "FOR" the proposals recommended by the Board of Directors.
0 · Reply
TheFrenchBuzz
TheFrenchBuzz Feb. 25 at 9:42 PM
$SGMO 1. The Voting Threshold: Why 50% of "Votes Cast" is enough Historically, in Delaware, a reverse split required the approval of a majority of all outstanding shares. This was a high bar for companies with many retail investors who often forget to vote. However, an amendment to the Delaware law (Section 242(d)(2) of the DGCL), which took effect on August 1, 2023, simplified things for listed companies (like Sangamo on the Nasdaq): Majority of Votes Cast: Now, to approve a reverse split, the "FOR" votes simply need to outnumber the "AGAINST" votes among the shares present or represented at the meeting. The "25%" Logic: For the vote to be valid, a quorum must be reached (usually 50% of the total shares for Sangamo). If exactly 50% of the shares are represented at the meeting, then 25% + 1 share of the total company is indeed enough to pass the resolution, as that represents the majority of the 50% present.
0 · Reply
809trader
809trader Feb. 25 at 9:40 PM
$SGMO short interest up by 9 million shares. Ouch
2 · Reply
Spider217
Spider217 Feb. 25 at 9:10 PM
$SGMO french your wrong on that need 51 percent of outstanding shares ck out CLVS when they failed
1 · Reply
Herr_Chicken
Herr_Chicken Feb. 25 at 9:09 PM
$SGMO We can all thank Vinay Prasad in large part for keeping our share price in the dumps despite promising Fabry data and an FDA-endorsed pathway to accelerated approval. This is from today WSJ op-ed about the FDA... "Food and Drug Administration chief Marty Makary boasted on these pages Monday about a new effort to allow more flexible reviews for drugs treating rare diseases. A good idea. But is the Commissioner paying attention to what his biologics chief Vinay Prasad is doing that conflicts with this goal? That’s the operating contradiction at FDA, after the agency this month rejected two rare disease drugs seeking accelerated approval. Congress in 2012 enacted the accelerated approval pathway to fast-track medicines that treat life-threatening diseases. Dr. Prasad is quietly undermining the program." https://www.wsj.com/opinion/vinay-prasad-fda-drug-approvals-disc-medicine-regenxbio-marty-makary-8488f514?mod=trending_now_opn_3
3 · Reply
TheFrenchBuzz
TheFrenchBuzz Feb. 25 at 8:58 PM
$SGMO They don’t need your vote they only need your brokers vote. There’s a 95% chance the reverse split will be approved.
0 · Reply
Latest News on SGMO
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Oct 30, 2025, 4:01 PM EDT - 4 months ago

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call


Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Jul 31, 2025, 4:05 PM EDT - 7 months ago

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call


Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12, 2025, 9:06 PM EDT - 10 months ago

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript


Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 4:35 PM EDT - 10 months ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call


NorthStarStats
NorthStarStats Feb. 26 at 2:05 AM
I forgot to post yesterday's stocks. Hopefully they did well today: $PRME Score: 100, $GMED Score 100, $EDIT Score 100, $LRMR Score 100, $SGMO Score 100
0 · Reply
Swamp_Yankee
Swamp_Yankee Feb. 26 at 12:06 AM
$SGMO Did you all catch JimiJo and metho on with Jim Crammer tonight? They clearly laid out the whole up and down. Great stuff.
1 · Reply
kiwiSurfer
kiwiSurfer Feb. 25 at 11:53 PM
$SGMO bingo
0 · Reply
Swamp_Yankee
Swamp_Yankee Feb. 25 at 11:51 PM
$SGMO Sandy won’t come out of his bedroom. He is all bent out of shape that Hellebuyck is getting the Presidential Medal of Freedom and not him. He is on his 3rd Papa John’s small cheese pizza.
0 · Reply
TheFrenchBuzz
TheFrenchBuzz Feb. 25 at 9:42 PM
$SGMO 2. Broker Votes: Can they vote on your behalf? This is the most strategic part for Sangamo’s management: "Routine" vs. "Non-Routine" Votes: Under stock exchange rules (NYSE/Nasdaq Rule 452), brokers are not allowed to vote without instructions on "important" matters (like electing directors or mergers). Reverse Splits are "Routine": Generally, a reverse split is classified as a routine matter by the exchanges because it doesn't change the intrinsic value of the investment. The Consequence: If you do not send voting instructions to your broker by the deadline, the broker has discretionary power to vote for you. In the vast majority of cases, brokers vote "FOR" the proposals recommended by the Board of Directors.
0 · Reply
TheFrenchBuzz
TheFrenchBuzz Feb. 25 at 9:42 PM
$SGMO 1. The Voting Threshold: Why 50% of "Votes Cast" is enough Historically, in Delaware, a reverse split required the approval of a majority of all outstanding shares. This was a high bar for companies with many retail investors who often forget to vote. However, an amendment to the Delaware law (Section 242(d)(2) of the DGCL), which took effect on August 1, 2023, simplified things for listed companies (like Sangamo on the Nasdaq): Majority of Votes Cast: Now, to approve a reverse split, the "FOR" votes simply need to outnumber the "AGAINST" votes among the shares present or represented at the meeting. The "25%" Logic: For the vote to be valid, a quorum must be reached (usually 50% of the total shares for Sangamo). If exactly 50% of the shares are represented at the meeting, then 25% + 1 share of the total company is indeed enough to pass the resolution, as that represents the majority of the 50% present.
0 · Reply
809trader
809trader Feb. 25 at 9:40 PM
$SGMO short interest up by 9 million shares. Ouch
2 · Reply
Spider217
Spider217 Feb. 25 at 9:10 PM
$SGMO french your wrong on that need 51 percent of outstanding shares ck out CLVS when they failed
1 · Reply
Herr_Chicken
Herr_Chicken Feb. 25 at 9:09 PM
$SGMO We can all thank Vinay Prasad in large part for keeping our share price in the dumps despite promising Fabry data and an FDA-endorsed pathway to accelerated approval. This is from today WSJ op-ed about the FDA... "Food and Drug Administration chief Marty Makary boasted on these pages Monday about a new effort to allow more flexible reviews for drugs treating rare diseases. A good idea. But is the Commissioner paying attention to what his biologics chief Vinay Prasad is doing that conflicts with this goal? That’s the operating contradiction at FDA, after the agency this month rejected two rare disease drugs seeking accelerated approval. Congress in 2012 enacted the accelerated approval pathway to fast-track medicines that treat life-threatening diseases. Dr. Prasad is quietly undermining the program." https://www.wsj.com/opinion/vinay-prasad-fda-drug-approvals-disc-medicine-regenxbio-marty-makary-8488f514?mod=trending_now_opn_3
3 · Reply
TheFrenchBuzz
TheFrenchBuzz Feb. 25 at 8:58 PM
$SGMO They don’t need your vote they only need your brokers vote. There’s a 95% chance the reverse split will be approved.
0 · Reply
Spider217
Spider217 Feb. 25 at 8:49 PM
$SGMO a reverse split vote with 400 million shares is not a slam dunk he knows it probably wont pass with retail he better have a different plan
1 · Reply
Swamp_Yankee
Swamp_Yankee Feb. 25 at 8:39 PM
$SGMO every investor today when it made that drop below .49
0 · Reply
Swamp_Yankee
Swamp_Yankee Feb. 25 at 8:38 PM
$SGMO if you bought more at .53 today thinking Sandy was gonna come through.
0 · Reply
Herr_Chicken
Herr_Chicken Feb. 25 at 8:28 PM
$SGMO $SGMO my prediction for the Q4 2025 conference call (early March? ) will be sangamo touting the filing of additional modules in its Fabry BLA and maybe some progress in signing up more individuals for the NAV 1.7 trial, and also some reference to cost-cutting by reducing staff. They will end with a generally rosy prediction that things are moving forward in their strategic plan. They will say some minor thing meant to show they are aware they need more cash. That same day (probably after the call) or the next they will issue an 8K announcing plans to call a reverse split shareholder vote. We will learn that as of the date of the earning call (or in the filing of the 8k for the shareholder vote) that their shares outstanding are now approximately 400 million.
4 · Reply
free2dream
free2dream Feb. 25 at 8:23 PM
$SGMO this is a $177M market cap, fabry BLA approval will jump this to $3-10 , not sure why are they dicking around still at 47 cents
1 · Reply
epet3
epet3 Feb. 25 at 7:58 PM
$SGMO WE WILL WIN IN THE END JUST LOCK TF IN!!!
0 · Reply
ErnieWorthing84
ErnieWorthing84 Feb. 25 at 7:58 PM
$SGMO "In addition, Sangamo agreed to reduce the exercise price on outstanding warrants to purchase 23,809,523 shares of common stock held by an investor from $1.00 to $0.4719 and extend the term of such warrants..."
0 · Reply
epet3
epet3 Feb. 25 at 7:57 PM
$SGMO TOMORROW GONNA BE A MOVIE
0 · Reply
kiwiSurfer
kiwiSurfer Feb. 25 at 7:35 PM
$SGMO bull pennant formed by desperate shorts dropping 1million $$$ to control pps … next leg up Soon 🔜
0 · Reply
TangoToEvora
TangoToEvora Feb. 25 at 7:26 PM
$SGMO I think the drop is not SGMO specific. It is a macro action. Same chart across the board. Now one might argue, the rise was also a macro actoon and nothing specific to SGMO. I can personally imagine it is. The gene techs are getting some market sympathy. One cannot deny the fact.
0 · Reply
Ozunoy
Ozunoy Feb. 25 at 7:13 PM
$SGMO garbage went 10÷ down the moment i bought
1 · Reply
1GreenDay99RedDays
1GreenDay99RedDays Feb. 25 at 7:05 PM
$SGMO lovely
0 · Reply